- Home
- OVV vs QGEN Comparison
OVV vs QGEN Comparison
Compare OVV & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVV
- QGEN
- Stock Information
- Founded
- OVV 2020
- QGEN 1986
- Country
- OVV United States
- QGEN Netherlands
- Employees
- OVV N/A
- QGEN N/A
- Industry
- OVV Oil & Gas Production
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OVV Energy
- QGEN Health Care
- Exchange
- OVV Nasdaq
- QGEN Nasdaq
- Market Cap
- OVV 11.9B
- QGEN 9.9B
- IPO Year
- OVV N/A
- QGEN 1996
- Fundamental
- Price
- OVV $43.92
- QGEN $39.51
- Analyst Decision
- OVV Strong Buy
- QGEN Buy
- Analyst Count
- OVV 16
- QGEN 8
- Target Price
- OVV $56.53
- QGEN $49.79
- AVG Volume (30 Days)
- OVV 4.3M
- QGEN 1.1M
- Earning Date
- OVV 05-06-2025
- QGEN 04-28-2025
- Dividend Yield
- OVV 2.73%
- QGEN 3.29%
- EPS Growth
- OVV N/A
- QGEN N/A
- EPS
- OVV 4.21
- QGEN 0.38
- Revenue
- OVV $8,943,000,000.00
- QGEN $1,978,214,000.00
- Revenue This Year
- OVV N/A
- QGEN $5.15
- Revenue Next Year
- OVV $6.30
- QGEN $6.49
- P/E Ratio
- OVV $10.43
- QGEN $105.49
- Revenue Growth
- OVV N/A
- QGEN 0.66
- 52 Week Low
- OVV $36.62
- QGEN $37.63
- 52 Week High
- OVV $55.95
- QGEN $47.93
- Technical
- Relative Strength Index (RSI)
- OVV 58.14
- QGEN 46.28
- Support Level
- OVV $41.77
- QGEN $39.31
- Resistance Level
- OVV $45.01
- QGEN $40.27
- Average True Range (ATR)
- OVV 1.29
- QGEN 0.55
- MACD
- OVV 0.36
- QGEN 0.16
- Stochastic Oscillator
- OVV 83.48
- QGEN 50.00
Stock Price Comparison Chart: OVV vs QGEN
About OVV Ovintiv Inc. (DE)
Ovintiv is a North American oil and natural gas exploration and production company. It focuses on the exploration and development of oil, NGLs, and natural gas reserves. The company has three segments: USA Operations, Canadian Operations, and Market Optimization.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).